|
 |
 |
 |
 |
 |
 |
|
|
|
531
|
FDA: Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements¹ßÇà
|
0 |
°ü¸®ÀÚ |
2016-11-30 |
273 |
|
|
530
|
FDA Inspection °ÅºÎ »ç·Ê¿Í Warning Letter
|
0 |
°ü¸®ÀÚ |
2016-11-26 |
387 |
|
|
529
|
½Ä¾àó: ｢¿ì¼ö°Ç°±â´É½ÄÇ° Á¦Á¶±âÁØ｣ °³Á¤ °í½Ã
|
0 |
°ü¸®ÀÚ |
2016-11-25 |
170 |
|
|
528
|
½Ä¾àó: º°Ç¥ 17. ¿ÏÁ¦ÀǾàÇ° Á¦Á¶ »õ·Î Ãß°¡
|
0 |
°ü¸®ÀÚ |
2016-11-22 |
364 |
|
|
527
|
USP New Chapter <1220>The Analytical Procedure Lifecycle ÃʾÈ
|
0 |
°ü¸®ÀÚ |
2016-11-16 |
269 |
|
|
526
|
Data Integrity°ü·Ã Warning Letter: À¯·´Á¦¾à»ç¿¡µµ[1]
|
0 |
°ü¸®ÀÚ |
2016-11-16 |
500 |
|
|
525
|
FDA: Guidance for Industry "Microbiology Data for Systemic Antibacterial Drugs" ¹ßÇà
|
0 |
°ü¸®ÀÚ |
2016-11-04 |
284 |
|
|
524
|
APIC: ¿ø·áÀǾàÇ° °øÀå ¼¼Ã´¹ë¸®µ¥À̼ǿ¡ °üÇÑ °¡ÀÌ´ø½º °³Á¤
|
0 |
°ü¸®ÀÚ |
2016-11-03 |
595 |
|
|
523
|
½Ä¾àó: ÀǾàÇ° µîÀÇ Á¦Á¶¾÷ ¹× ¼öÀÔÀÚÀÇ ½Ã¼³±âÁØ·É °³Á¤ 2018³â 10¿ù29ÀÏ ½ÃÇà
|
0 |
°ü¸®ÀÚ |
2016-11-01 |
358 |
|
|
522
|
½Ä¾àó: ÀǾàÇ° µîÀÇ ¾ÈÀü¿¡ °üÇÑ ±ÔÄ¢ °³Á¤ 2016³â 10¿ù 28ÀÏ ½ÃÇà
|
0 |
°ü¸®ÀÚ |
2016-11-01 |
332 |
|
|
